SecBot SecBot
8-K ·Filed Nov 5, 2026

ELUT

ELUTIA INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 11h ago SEC0001104659-26-123316
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the NXT-41 FDA clearance decision expected in Q4 2026 and the NXT-41x FDA submission in the same quarter. Monitor for FDA decisions and any Cardiovascular business transaction, which could extend the cash runway further.

DirectionNeutral
Confidencehigh
Horizonweeks

NXT-41

▲ Bullish Named in this 8-K
Impact
Phase
Filed/510(k) submission
Time to market
NXT-41 (base matrix) clearance decision expected Q4 2026 (within ~2 months). NXT-41x (antibiotic-eluting) clearance expected Q2 2027, with first full year of commercial launch targeted for 2028.
Next catalyst
None dated

What to watchWatch for the FDA 510(k) clearance decision on NXT-41 (base biologic matrix), expected by end of Q4 2026 (any day now through December). A clearance would validate the platform and clear the path for NXT-41x submission. The bigger catalyst is NXT-41x clearance expected Q2 2027, which would open the $1.5B breast reconstruction market. The company is fully funded through launch, removing near-term dilution risk. However, as a micro-cap single-product story, any regulatory delay or negative FDA feedback would hit the stock hard.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.8374
T+0 close · Nov 5, 2026 · via day close
Latest settled
−2.08%
T+5 · $0.8200 · next T+20 in 20d
Vs SPY
−4.67%
α at T+5
Latest observation
−0.23%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $0.8374entry
  2. T+1 · 8d ago −0.18%α −2.55% · $0.8359
  3. T+5 · 4d ago −2.08%α −4.67% · $0.8200
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Elutia reported Q3 2026 net sales of $1.1M (+20.4% YoY) but a net loss from continuing operations of $6.5M, significantly wider than the $1.0M loss a year ago, driven by higher R&D spending on NXT-41x. The company secured $26M in non-dilutive capital, completed the SimpliDerm sale, and is on track to submit NXT-41x to the FDA in Q4 2026, with cash runway through the first full year of commercialization.

Key Financial Metrics

Revenue
$1.1M
est $1.0M · +13.7% · +20.4% YoY
Gross Margin
61.7%

Key Facts

  • Q3 2026 net sales from continuing operations were $1.1M, up 20.4% from $0.9M in Q3 2025.
  • Net loss from continuing operations was $6.5M, compared to a $1.0M loss in Q3 2025.
  • Adjusted EBITDA loss was $5.6M, compared to a $3.4M loss in the prior year period.
  • Cash and cash equivalents at September 30, 2026 were $29.1M; an additional $8M escrow release received on October 1, 2026.
  • Elutia added $26M in capital without an equity offering via the SimpliDerm sale ($8M), Boston Scientific escrow release ($8M), and Avenue Capital loan ($10M funded, $5M available post-clearance).
  • NXT-41x GLP rabbit study met prespecified endpoints, with no viable bacteria recovered after MRSA and E. coli challenges.
  • NXT-41 FDA clearance decision anticipated in Q4 2026; NXT-41x FDA submission planned for Q4 2026.
  • Cardiovascular revenue grew 20% YoY to $1.1M in Q3 2026; adjusted gross margin of 85.5%.
  • GAAP gross margin improved to 61.7% from 52.8%; adjusted gross margin was 85.5% from 81.3%.
  • Total operating expenses were $7.6M, up from $6.4M, driven by a $1.9M increase in R&D.

Financial Impact

Q3 2026 continuing ops net sales $1.1M; net loss from continuing ops $6.5M; cash $29.1M; $26M raised in non-dilutive capital

revenuenet losscashR&D spend

Segment Breakdown

SegmentRevenueGrowth
Cardiovascular$1.1M+20.4%

Risk Factors

  • NXT-41 and NXT-41x may not receive FDA clearance on the anticipated timeline or at all.
  • The company is pre-revenue for its lead pipeline program and continues to generate significant operating losses.
  • Dependence on a limited number of third-party suppliers, including Cook Biotech as sole supplier for Cardiovascular products.
  • FiberCel and VBM litigation remains a contingent liability, though the balance has been reduced.
  • The company must maintain compliance with Nasdaq listing requirements.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-123316
Document: elut-20261105x8k.htm0001104659-26-123316
Document: 0001104659-26-123316-index-headers.html0001104659-26-123316
Document: 0001104659-26-123316-index.html0001104659-26-123316
Document: 0001104659-26-123316.txt0001104659-26-123316
8-K Data (Synthetic)0001104659-26-123316

Track record

7 reports on ELUT

Performance horizon
Filters
  1. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  2. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
  3. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
  4. Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
  5. Jun 16, 202621w ago 8-K Neutral 3/10 Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
  6. May 14, 202626w ago 8-K Neutral 5/10 Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
  7. Mar 11, 202635w ago 8-K Mixed 7/10 Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026